Cibus Therapeutics is a privately held, clinical-stage biopharmaceutical company backed by a group of experienced biotech investors committed to advancing innovative therapies for gastrointestinal diseases driven by chronic inflammation.

We are focused on translating breakthrough science into meaningful treatments for patients with urgent unmet needs, such as chronic pancreatitis and ulcerative colitis. Our investors share our vision of building a differentiated pipeline of therapies that modulate inflammatory signaling to improve patients’ quality of life.